| domain | core facts | suggested ontology terms/IDs | key evidence/statistics |
|---|---|---|---|
| Disease definition/identifier | Congenital heart disease (CHD) is a heterogeneous group of structural heart defects present at birth; it is the most commonly detected congenital anomaly. Use disease-level aggregated resources rather than individual EHR-derived evidence for core definition. | MONDO:0005453 congenital heart disease; MeSH: Congenital Heart Defects | Affects up to ~1% of live-born neonates; global prevalence often cited as 1–2% of infants (pqac-00000004, pqac-00000003) |
| Major lesion phenotypes | Representative major lesions include ventricular septal defect, tetralogy of Fallot, hypoplastic left heart syndrome, transposition of the great arteries, left ventricular outflow tract obstruction, and single-ventricle disease. | HP:0001629 Ventricular septal defect; HP:0001636 Tetralogy of Fallot; HP:0004383 Hypoplastic left heart; HP:0001651 Transposition of the great arteries; HP:0005105 Abnormality of left ventricular outflow tract; HP:0004762 Single ventricle | TOF and HLHS were specifically analyzed in recent single-cell/machine-learning work; LVOTO had relatively high diagnostic genetic yield in isolated CHD cohorts (pqac-00000000, pqac-00000003) |
| Genetics: causal/susceptibility genes | Recurrently implicated CHD genes include NKX2-5, GATA4, GATA6, TBX20, TBX1, GDF1, MYH6, TNNT2, TFAP2B, TAB2, GJA1; BMP4 has recent evidence as a causative/predisposing gene. | HGNC: NKX2-5, GATA4, GATA6, TBX20, TBX1, GDF1, MYH6, TNNT2, TFAP2B, TAB2, GJA1, BMP4; MONDO:0800441 NKX2.5-related congenital, conduction and myopathic heart disease | Open Targets lists strongest CHD associations for NKX2-5 and GATA4; 2024 familial study identified BMP4 p.Tyr106* segregating with CHD and loss of induction of NKX2-5/TBX20 targets (pqac-00000008, pqac-00000001) |
| Chromosomal/syndromic contributors | Important chromosomal or syndromic causes include trisomy 21, trisomy 18, trisomy 13, Turner syndrome, 22q11.2 deletion/DiGeorge syndrome, Williams syndrome, CHARGE syndrome, and Noonan syndrome. | 22q11.2 deletion syndrome; trisomy 21; trisomy 18; trisomy 13; Turner syndrome; Williams syndrome; CHARGE syndrome; Noonan syndrome | In a 2024 NICU cohort, 17% received a genetic diagnosis; most frequent diagnoses were 22q11.2 deletion and CHARGE, followed by Noonan and Williams syndromes (pqac-00000004, pqac-00000001) |
| Genetic testing/diagnostic yield | Current evidence supports chromosomal microarray (CMA) and next-generation sequencing (NGS/WGS/WES) in severe or syndromic CHD; isolated CHD can still yield diagnoses. | CMA; WES; WGS; copy-number variant analysis | CMA diagnostic yield: 14.6% in 440 infants and 10.1% in 188 NICU neonates; overall genetic diagnosis 17% in the NICU cohort; isolated CHD still had diagnostic findings (6.5% CMA-positive in one cohort; ~3% diagnosed in another cohort) (pqac-00000003, pqac-00000004) |
| Environmental/non-genetic risk factors | CHD risk is influenced by maternal and environmental exposures, including maternal diabetes, obesity, gestational hypertension, harmful chemicals, noise, antidepressant exposure, and family genetic history. | CHEBI terms not resolved here; exposure concepts: maternal diabetes, maternal obesity, SSRI/SNRI exposure | Updated umbrella review found convincing/highly suggestive evidence for maternal DM, obesity, folic acid supplementation, antidepressants, gestational hypertension, decoration materials, harmful chemicals, and noise exposure associations (pqac-00000006) |
| Protective factors | Maternal folic acid supplementation is repeatedly discussed as a modifiable factor associated with reduced CHD risk, although evidence varies by lesion and study design. | folic acid supplementation | Umbrella review identified folic acid supplementation among the strongest non-genetic factors evaluated for CHD prevention relevance (pqac-00000006) |
| Developmental pathways/mechanisms | CHD arises from disruption of cardiac morphogenesis involving second heart field, neural crest, epicardial progenitors, and pathways such as BMP, Notch, Wnt, TGF-beta/Smad, laterality/NODAL signaling, and transcriptional programs controlling septation and outflow tract development. | GO:0007507 heart development; GO:0060916 cardiac septum morphogenesis; GO:0001947 heart looping; GO:0007220 Notch signaling pathway; GO:0030509 BMP signaling pathway; GO:0016055 Wnt signaling pathway; GO:0007179 TGF-beta receptor signaling pathway | Recent reviews emphasize genetic plus environmental regulation of fetal heart development; single-cell/machine-learning studies also point to pathway disruption across CHD subtypes (pqac-00000006, pqac-00000000) |
| Cell types involved | Key implicated cardiac cell populations include cardiomyocytes, endothelial cells, cardiac fibroblasts, neural crest-derived cells, second heart field progenitors, and epicardial progenitor cells. | CL:0000746 cardiac muscle cell; CL:0000115 endothelial cell; CL:0000057 fibroblast; CL:0000349 neural crest cell; CL:0002494 epicardial cell | 2024 single-cell analysis examined 73,296 cardiomyocytes, 35,673 endothelial cells, and 21,034 fibroblasts across CHD-related conditions (pqac-00000000, pqac-00000002) |
| Anatomy/localization | Primary structures affected include cardiac septa, ventricular chambers, atria, outflow tract, great arteries, valves, coronary arteries, aorta, and conduction system. | UBERON:0000948 heart; UBERON:0002084 cardiac ventricle; UBERON:0002079 atrium; UBERON:0001981 cardiac septum; UBERON:0003129 outflow tract; UBERON:0000947 aorta | Reviews of chromosomal CHD and imaging emphasize abnormalities across chambers, valves, coronary arteries, aorta, and conduction tissue (pqac-00000001, pqac-00000009) |
| Imaging/clinical diagnostics | Core diagnostics include echocardiography, fetal echocardiography, genetic testing, and cardiovascular magnetic resonance (CMR) for detailed anatomy, hemodynamics, and postoperative follow-up. | fetal echocardiography; cardiac MRI/CMR | CMR provides high-detail anatomy, chamber volumes, flow, tissue characterization, and postoperative assessment without ionizing radiation; prenatal diagnosis relies heavily on fetal echocardiography (pqac-00000009) |
| Treatment/interventions | Management includes surgical repair/palliation, catheter-based intervention, balloon valvuloplasty, staged Norwood/Glenn/Fontan procedures for HLHS, medications for heart failure/arrhythmia/hemodynamics, implantable defibrillators in selected cases, and heart transplantation for severe disease. | NCIT: Cardiac Surgical Procedure; NCIT: Catheterization; NCIT: Balloon Valvuloplasty; NCIT: Fontan Procedure; NCIT: Norwood Procedure; NCIT: Glenn Procedure; NCIT: Heart Transplantation; NCIT: Implantable Cardioverter Defibrillator | Recent summaries note surgery as highest-risk/highest-cost, catheter procedures as resource-intensive, and lifelong medication burden; severe cases may need transplant or ICDs (pqac-00000012, pqac-00000009) |
| Outcomes/prognosis | Mortality and complication burden remain substantial despite improved survival. SCD is a major late complication, especially in complex lesions and repaired TOF. | HP:0001644 Sudden cardiac death; HP:0011675 Arrhythmia | SCD incidence in CHD cohorts reported at 0.28–2.7% annually; TOF 0.9–1.5% annually; SCD may account for up to 25% of deaths in CHD populations (pqac-00000007) |
| Omics and advanced models | Emerging CHD research uses single-cell transcriptomics, RNA-seq, metabolomics, machine learning, iPSC-derived cardiomyocytes, CRISPR rescue experiments, and organoid systems. | single-cell RNA-seq; metabolomics; iPSC-CM disease model; CRISPR/Cas9 | iPSC-CM models identified mitochondrial dysfunction/oxidative stress in HLHS and showed rescue of MYH6-R443P dysfunction by gene editing; metabolomics studies linked perioperative metabolites to mortality, AKI, and neurologic outcomes (pqac-00000011, pqac-00000013, pqac-00000002) |
| Current real-world studies/trials | Active real-world implementation includes national/regional registries, transition programs, arrhythmia imaging studies, prenatal multi-omics studies, device studies, and lifecycle CHD registries. | ClinicalTrials.gov: NCT02258724, NCT06611787, NCT06705543, NCT07425132, NCT07559253 | Beijing Anzhen lifecycle registry plans 100,000 patients with long-term follow-up; other active studies include adult CHD registry and fetal complex CHD multi-omics investigation (pqac-00000010) |
| Evidence caveats | CHD is highly heterogeneous; many estimates pool diverse lesions, ages, and syndromic/isolated cases. Diagnostic yields vary by cohort selection and testing strategy; some cited evidence comes from reviews or registry descriptions rather than lesion-specific randomized trials. | Evidence annotation recommended: human clinical, registry, review, model organism, in vitro | Several excerpts note limited access due to socioeconomic disparities, small sample sizes in omics studies, and imperfect sensitivity of dysmorphology-based screening (pqac-00000009, pqac-00000013, pqac-00000003) |


*Table: This table condenses the conversation’s established congenital heart disease facts into ontology-ready domains for a knowledge base. It highlights identifiers, phenotypes, genes, pathways, anatomy, diagnostics, treatments, and key evidence caveats with citeable context IDs.*